{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:26:24Z","timestamp":1790508384805,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81473280"],"award-info":[{"award-number":["81473280"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81302826"],"award-info":[{"award-number":["81302826"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Provincial Key Laboratory Project, Liaoning","award":["LZ2015027"],"award-info":[{"award-number":["LZ2015027"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Phytomedicine"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.phymed.2016.12.006","type":"journal-article","created":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T18:33:09Z","timestamp":1481653989000},"page":"83-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor"],"prefix":"10.1016","volume":"25","author":[{"given":"Xingping","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokui","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0699-8452","authenticated-orcid":false,"given":"Kexin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phymed.2016.12.006_bib0001","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1172\/JCI41636","article-title":"The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans","volume":"122","author":"Benhamed","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phymed.2016.12.006_bib0002","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0016-5085(98)70590-6","article-title":"Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes","volume":"114","author":"Berson","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phymed.2016.12.006_bib0003","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phymed.2016.12.006_bib0004","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2015.01.005","article-title":"Can NASH lipidome provide insight into the pathogenesis of obesity-related non-alcoholic fatty liver disease?","volume":"62","author":"Birerdinc","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phymed.2016.12.006_bib0005","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/gast.2002.34168","article-title":"Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma","volume":"123","author":"Bugianesi","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phymed.2016.12.006_bib0006","first-page":"685","article-title":"The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis","volume":"34","author":"Cariou","year":"2008","journal-title":"Metabolism"},{"key":"10.1016\/j.phymed.2016.12.006_bib0007","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s11095-014-1483-3","article-title":"Protective effects of calycosin against CCl4-induced liver injury with activation of FXR and STAT3 in mice","volume":"32","author":"Chen","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phymed.2016.12.006_bib0008","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phymed.2016.12.006_bib0009","first-page":"649","article-title":"Peroxisome proliferator-activated receptors: nuclear control of metabolism","volume":"20","author":"Desvergne","year":"1999","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.phymed.2016.12.006_bib0010","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis","volume":"43","author":"Farrell","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.phymed.2016.12.006_bib0011","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phymed.2016.12.006_bib0012","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1124\/jpet.105.084905","article-title":"A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis","volume":"314","author":"Fiorucci","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phymed.2016.12.006_bib0013","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.febslet.2010.04.004","article-title":"An allostatic control of membrane lipid composition by SREBP1","volume":"584","author":"Hagen","year":"2010","journal-title":"FEBS Lett."},{"key":"10.1016\/j.phymed.2016.12.006_bib0014","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/hepr.12333","article-title":"Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: current concepts and remaining challenges","volume":"45","author":"Hashimoto","year":"2015","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.phymed.2016.12.006_bib0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2015.03.005","article-title":"Effect of resveratrol on experimental non-alcoholic steatohepatitis","volume":"95-96","author":"Heeboll","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phymed.2016.12.006_bib0016","doi-asserted-by":"crossref","first-page":"21833","DOI":"10.3390\/ijms141121833","article-title":"Rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"14","author":"Imajo","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2016.12.006_bib0017","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/hep.20170","article-title":"Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice","volume":"39","author":"Ip","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.phymed.2016.12.006_bib0018","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.metabol.2016.02.013","article-title":"Non-alcoholic fatty liver disease and liver transplantation","volume":"65","author":"Khan","year":"2016","journal-title":"Metabolism"},{"issue":"Suppl,","key":"10.1016\/j.phymed.2016.12.006_bib0019","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.ypmed.2011.12.018","article-title":"Isoflavones as a smart curer for non-alcoholic fatty liver disease and pathological adiposity via ChREBP and Wnt signaling","volume":"54","author":"Kim","year":"2012","journal-title":"Prev. Med."},{"key":"10.1016\/j.phymed.2016.12.006_bib0020","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.phymed.2016.12.006_bib0021","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ptr.4759","article-title":"Isolation of anti-inflammatory fractions and compounds from the root of Astragalus membranaceus","volume":"27","author":"Lai","year":"2013","journal-title":"Phytother. Res."},{"key":"10.1016\/j.phymed.2016.12.006_bib0022","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/914938","article-title":"NAFLD, estrogens, and physical exercise: the animal model","volume":"2012","author":"Lavoie","year":"2012","journal-title":"J. Nutr. Metab."},{"key":"10.1016\/j.phymed.2016.12.006_bib0023","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.phymed.2016.08.003","article-title":"The chloroform extract of cyclocarya paliurus attenuates high-fat diet induced non-alcoholic hepatic steatosis in Sprague Dawley rats","volume":"23","author":"Lin","year":"2016","journal-title":"Phytomedicine"},{"key":"10.1016\/j.phymed.2016.12.006_bib0024","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s00018-014-1805-y","article-title":"Nuclear bile acid signaling through the farnesoid X receptor","volume":"72","author":"Mazuy","year":"2015","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.phymed.2016.12.006_bib0025","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phymed.2016.12.006_bib0026","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1210\/me.2002-0120","article-title":"Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor","volume":"17","author":"Pineda Torra","year":"2003","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.phymed.2016.12.006_bib0027","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3748\/wjg.v21.i4.1099","article-title":"Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease","volume":"21","author":"Qiu","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.phymed.2016.12.006_bib0028","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jhep.2015.02.041","article-title":"Current efforts and trends in the treatment of NASH","volume":"62","author":"Ratziu","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phymed.2016.12.006_bib0029","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tox.2013.08.011","article-title":"The adverse outcome pathway concept: a pragmatic tool in toxicology","volume":"312","author":"Vinken","year":"2013","journal-title":"Toxicology"},{"key":"10.1016\/j.phymed.2016.12.006_bib0030","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.bbrc.2014.05.117","article-title":"Cycloastragenol, a triterpene aglycone derived from Radix astragali, suppresses the accumulation of cytoplasmic lipid droplet in 3T3-L1 adipocytes","volume":"450","author":"Wang","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phymed.2016.12.006_bib0031","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phymed.2016.12.006_bib0032","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.plipres.2015.05.002","article-title":"Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research","volume":"59","author":"Willebrords","year":"2015","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.phymed.2016.12.006_bib0033","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1158\/0008-5472.CAN-06-1078","article-title":"Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.phymed.2016.12.006_bib0034","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1142\/S0192415X10007816","article-title":"Protective effect of puerarin on acute alcoholic liver injury","volume":"38","author":"Zhao","year":"2010","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.phymed.2016.12.006_bib0035","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1007\/s13277-015-3194-8","article-title":"Calycosin induces apoptosis in human ovarian cancer SKOV3 cells by activating caspases and Bcl-2 family proteins","volume":"36","author":"Zhou","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.phymed.2016.12.006_bib0036","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.fct.2013.04.018","article-title":"Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH) via modulation of PPARa and SREBP-1","volume":"58","author":"Ziamajidi","year":"2013","journal-title":"Food Chem. Toxicol."}],"container-title":["Phytomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711316302537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711316302537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T21:51:32Z","timestamp":1536184292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0944711316302537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":36,"alternative-id":["S0944711316302537"],"URL":"https:\/\/doi.org\/10.1016\/j.phymed.2016.12.006","relation":{},"ISSN":["0944-7113"],"issn-type":[{"value":"0944-7113","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor","name":"articletitle","label":"Article Title"},{"value":"Phytomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phymed.2016.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}]}}